73267-74-0 Usage
Uses
Used in Pharmaceutical Industry:
5-Bromo-2-(o-tolyloxy)pyrimidine is used as an intermediate in the synthesis of various pharmaceutical substances. Its unique structure and reactivity make it a key component in the development of new drugs and medications.
Used in Organic Synthesis:
5-Bromo-2-(o-tolyloxy)pyrimidine is used as a building block in organic synthesis, allowing chemists to create a wide range of complex molecules with potential applications in various fields, including medicine, agriculture, and materials science.
Used in Research and Development:
5-Bromo-2-(o-tolyloxy)pyrimidine is utilized in research and development settings, where it serves as a valuable tool for studying the properties and reactions of pyrimidine derivatives. This knowledge can be applied to the design and synthesis of new compounds with specific functions and properties.
Used in Laboratory and Manufacturing:
5-Bromo-2-(o-tolyloxy)pyrimidine is available for purchase for use in laboratories and manufacturing processes, where it can be incorporated into the production of pharmaceuticals and other chemical products. Proper storage and handling are essential due to its potential reactivity.
Check Digit Verification of cas no
The CAS Registry Mumber 73267-74-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,3,2,6 and 7 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 73267-74:
(7*7)+(6*3)+(5*2)+(4*6)+(3*7)+(2*7)+(1*4)=140
140 % 10 = 0
So 73267-74-0 is a valid CAS Registry Number.
InChI:InChI=1/C11H9BrN2O/c1-8-4-2-3-5-10(8)15-11-13-6-9(12)7-14-11/h2-7H,1H3
73267-74-0Relevant articles and documents
Synthesis and antitumor activities of novel benzoylphenylurea derivatives
Okada,Koyanagi,Yamada,Haga
, p. 2308 - 2315 (2007/10/02)
Seventy novel benzoylphenylurea compounds were synthesized and their antitumor activities were examined in vivo against P388 leukemia. N-(2-Nitrobenzoyl)-N'-[4-(2-pyrimidinyloxy)phenyl]ureas showed the highest antitumor activities when dosed intraperitoneally or orally. Their structure-activity relationships were examined with particular focus on the position and the variety of substituent on each aryl ring.
